NanoViricides, Inc
nanoviricides.comWhat Do They Do?
Develops antiviral drugs for patients with viral infections, including COVID, mpox and Ebola.
10-K for FY2026, filed Sep 28, 2026We are engaged in developing a class of drugs, that we call nanoviricides™, using a platform technology based on the application of…View ↗
Our first clinical stage drug candidate, NV-387, has completed Phase Ia/Ib human clinical trial for the evaluation of safety and…View ↗
Two Phase II clinical trials, (i) NV-387 Oral Gummies for the Treatment of Mpox (Monkeypox) and (ii) NV-387 Oral Gummies for the Treatment…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2026, filed Sep 28, 2026
How Are They Changing?
Broader antiviral program
The earlier report described its coronavirus candidate entering human trials; the latest describes oral gummies for mpox and Ebola trials and a trial spanning respiratory viruses.
10-K for FY2023, filed Oct 13, 2023 10-K for FY2026, filed Sep 28, 2026NV-CoV-2, the drug we developed in response to the COVID-19 pandemic, has entered Phase 1a/1b human clinical trials sponsored by our…View ↗
Who Do They Compete With?
Competes with Pfizer, Chimerix, Roche, Glaxo SmithKline, BioCryst, Shionogi, Gilead, Bristol-Myers Squibb, Boehringer Ingelheim, Merck &, SIGA, Emergent Bio, Aventis Pasteur, Chiron, and Novartis
10-K for FY2026, filed Sep 28, 2026Several companies have advanced drug candidates for the management of COVID-19. Remdesivir, an antiviral drug, has received full approval…View ↗
Loading...
